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Abstract-Doxorubicin (DOX) is one of the most effective anti-cancer drugs in oncology, but 
may cause a cumulative dose-dependent cardiomyopathy in a number of cancer patients. The effect 
of DOX on the heart was studied in mice treated with i.v. injections of 2 mglkg &y measuring 
morphometric parameters, including nuclear index (number of non-myocytes/number of myocyte 
nuclei), reticulin index (reticulin area/number of myocyte transsections), nuclear transsectional 
area, myocyte transsectional area, capillary index (number of capillaries/number of myoqte 
tramsections) and capillary transsectional area. The highest significant difference between control 
mice and DO?i-treated mice was observed immediateb after the 12th dose of DOX except for 
the two capillary parameters. The highest level of significance for these two parameters was 
obtained 12 weeks after the end of DOX treatment. In contrast to the observations in rats, mice 
did not develop a nephrotic syndrome during treatment with DOX. The morphometric analysis 
oJ’myocardia1 changes in mire, as a quantitative and objective method, seems to be a good model 
for comparative studies on cardiomyopathy induced by anthracycline analogues. 
INTRODUCTION 
THE UTILIZATION of anthracycline antibiotics in 
clinical oncology is limited because of dose-related 
cardiotoxicity. The magnitude of this clinical prob- 
lem is particularly great for breast cancer, where 
the decision to apply this anticancer drug in studies 
ofadjuvant chemotherapy must be balanced against 
the risk of cardiotoxicity in a group including poten- 
tially cured individuals. Cardiotoxicity has been 
observed in man and animals, although species 
differences exist [l-3]. The rabbit and monkey have 
been reported to exhibit congestive heart failure 
associated with cardiomyopathy [4]. There is a lack 
of understanding of the causative mechanisms of 
anthracycline cardiotoxicity. Possible strategies 
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that may circumvent this cardiotoxicity include the 
development of anthracycline analogues with 
reduced cardiotoxicity, alteration of the schedule 
and development of cardioprotective agents. 
Billing-ham el el[5] have introduced a numerical 
grading system for the recording of morphological 
cardiac changes following treatment with anthracy- 
clines. A similar scoring system was used by Bcrt- 
azolli et al. [l] in a mouse model. Obviously, it is a 
prerequisite to use an unambiguous animal model 
and sensitive parameters of cardiotoxicity for any 
research in this area. Several authors have described 
morphological, biochemical and functional alter- 
ations in the heart induced by anthracyclines [5-71. 
The morphological parameters have been shown to 
develop early and to be most reliable for detecting 
drug-related cardiomyopathy [3]. In order to estab- 
lish a causative relationship between the drug and 
the morphological changes, the findings in labora- 
tory animals should be reproducible. We have 
shown in a recent study that rats should not bc used 
for cardiotoxicity studies on anthracyclines because 
they develop a severe nephrotic syndrome. In pur- 
omycin-treated rats, a common model for the neph- 
rotic syndrome, cardiac damage was observed simi- 
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lar to that observed in DOX treated rats [8, 91. In 
the present study cardiotoxicity was evaluated in 
mice by quantification of histomorphological 
characteristics from areas in transsectional sections 
of the heart after DOX treatment. Special attention 
was also directed to urinary protein excretion. The 
data indicate that the evaluation of anthracycline 
cardiotoxicity in mice can be carried out by a 
quantitative morphometric approach. 
MATERIALS AND METHODS 
Seventy-eight female Swiss mice (Central Insti- 
tute for Experimental Animals, Zeist, The Nether- 
lands) with an average weight of 25 + 2 g were 
randomly distributed into a control group (31 ani- 
mals) and a DOX-treated group (48 animals). Mice 
were maintained in plastic cages in a standardized 
environment and fed a laboratory diet and water ad 
libitum. 
Doxorubicin, dissolved in saline, was injected i.v. 
twice a week (Monday and Thursday) at a dose of 
2 mg/kg/day 12 times. A treatment-free interval of 
2 weeks was introduced after the 4th injection in 
order to allow recovery of bone marrow function. 
Six DOX-treated mice and six control animals were 
killed at the following time points (in control groups 
V and VII only 3 and 4 animals respectively were 
killed): 1 week (DOX I, C I) 2 weeks (DOX II, 
C II), 6 weeks (DOX III, C III), 8 weeks 
(DOX IV, C IV), 12 weeks (DOX V, C V), 14 
weeks (DOX VI), 16 weeks (DOX VII, C VII) 
and 20 weeks (DOX VIII). 
Every week DOX-treated mice were randomly 
selected and kept in metabolic cages for 24 h. Urine 
volume was measured and urine protein excretion 
was determined with the Bio-Rad protein assay 
(Bio-Rad Laboratories, Richmond, Cal., U.S.A.), 
in order to exclude the presence of a nephrotic 
syndrome. The hearts were quickly removed from 
the mice at thoracotomy, which was performed 
under ether anaesthesia, and immersed in 10 mM 
CaCI, solution for 5 min. Subsequently, each heart 
was fixed in 2% glutaraldehyde in 0.1 M phosphate 
buffer at pH 7.4 for 48 h. All hearts were cut in a 
transverse plane, perpendicular to the ventricular 
septum, three times with the first transsection 2 mm 
below the cardiac skeleton. 
The first slice of 1 mm thickness at the apical 
side of the first plane was processed for paraffin 
embedding with a standard technique. Paraffin 
sections of 4 FM were cut and stained with haema- 
toxylin and eosin (HE staining). A second slice of 
0.5 mm thickness was cut on the skeletal side of the 
first plane and processed in methacrylate according 
to standard procedures. After embedding, semi-thin 
sections of 1 km were cut and stained with toluidine 
blue or PAS or Gomorri’s silver stain. 
Nuclear index (NZ) 
From each heart, three areas stained with 
HE-left ventricular free wall subendocardial, left 
ventricular papillary muscle and left ventricular 
septum subendocardial-were photographed twice 
on a 35 mm diapositive film using a 200 x micro- 
scopic magnification. Colour slides were projected 
on a 120 X 80 screen subdivided by black lines 
into 10 X 10 cm squares. Colour slides were ana- 
lysed by counting non-myocyte nuclei and myocyte 
nuclei per square. The slides-two per area-were 
randomly selected. The origin of the specimen was 
unknown to the investigator. The nuclear index 
which is the ratio between the number of non- 
myocyte nuclei and that of the myocyte nuclei, was 
calculated for all three locations of each heart. 
Reticulin index (RI) 
Paraffin sections were stained with Gomorri’s 
silver stain and photomicrographs with a micro- 
scopic magnification of 400 X were made on 
35 mm Agfa Ortho 25 IS0 film. Again, the three 
areas in each heart were analysed in duplicate. The 
negatives were magnified to prints of 6 X 9 cm. 
The nuclei visible in the prints were cut out. Rcticu- 
lin areas were measured by a Quantimet (Cam- 
bridge Instruments, Milbourne, Royston, U.K.) 
with a fixed threshold setting. The RI was calcu- 
lated as the ratio of reticulin area and number of 
myocytc transsections. The average RI was deter- 
mined for each group of animaIs. 
Nuclear and myocyte transsectional areas (NTA, MTA) 
Photographs of PAS stained semi-thin sections 
were enlarged to 30 X 40 cm with a microscopic 
magnification of 400 X. Cells transsected in the 
nuclear zone were identified by number. These 
cells were outlined on a digitizing tablet (Bit-pad, 
Summagraphics, on-line to a PDP-1173 computer) 
as were their nuclei. Two photographs per area 
were necessary to obtain the minimum sample size. 
Mean MTA and NTA were calculated for all animal 
groups. 
Capillary transsectional area (CTA) and capillary index 
(Cr) 
The same photographs as used for the determi- 
nation of the MTA and NTA were analysed for 
CTA and CI. The capillaries were outlined on a 
digitizing tablet. Mean CTA was calculated for 
each animal group. The CI was calculated by 
dividing the total number of capillaries by the 
number of myocyte transsections. This index was 
determined for all animal groups. 
Statistical methods 
Differences between DOX and control groups 
were analyscd by Wilcoxon’s rank sum test. The 
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minimal sample size was determined by the running 
mean method. Reproducibility and other statistical 
parameters related to the reliability of morpho- 
metric measurements have been reported previously 
PI. 
RESULTS 
Protein excretion, urinary output and body weight 
During the experiment no nephrotic syndrome 
was observed in the DOX-treated mice. Mean 
urinary protein was 0.82 + 0.28 mg/24 h in the 
control group and 0.85 If: 0.28 mg/24 h in the 
DOX groups. Mean urine volume was 6.6 t 2.8 
ml/24 h in controls and 5.6 5 4.0 ml/24 h in the 
DOX group. There was no significant difference 
between controls and DOX-treated mice. Body 
weight was constant during DOX administration. 
Mean body weight was 27.5 I+_ 0.4 g in the control 
group and 28.4 5 0.5 g in the DOX groups, which 
is not statistically different. 
Morphometric analysis 
The results obtained with the morphometric par- 
ameters of heart tissues of DOX-treated mice and 
controls are summarized in Table 1. All six par- 
ameters examined in this study changed as a result 
of the DOX treatment. During the period of DOX 
treatment the values of NI, RI, NTA and MTA 
steadily increased. After the period of DOX admin- 
istration there was a slight decrease in NI, an 
impressivr decrease in MTA and a plateau in NTA 
and RI. In the control groups NTA and MTA 
remained stable, while NI and RI gradually 
increased. NI and the NTA rcachcd the highest level 
of significance (P < 0.001) after administration of 
16 and 24 mg DOX. RI and MTA reached the 
highest level of significance (P < 0.01) after thr 
administration of 16 and 24 mg DOX. The first 
significant differences (P < 0.05) between DOX 
and control groups were found after 2 weeks, i.e. at 
a cumulative dose of 8 mg DOX. 
In contrast to the four parameters mentioned 
above it appeared that the pattern of CI and CT.4 
was different. CI increased in the DOX-trcatcd 
group and did not become significantly different to 
that of the control group until 8 weeks, while the 
highest lcvcl of significance was reached after 20 
weeks. The increase in CI correlated with a gradual 
increase in the number of capillaries present at the 
start of the experiment. In the initial weeks CI 
increased slightly in the control group, while it 
reached a plateau value after 6 weeks. CT.4 
decreased constantly in the ADM groups. The 
highest level of significance (P < 0.0 1) was reached 
in the 20th week. In the control group a slight 
increase was observed followed by a vcrv slow 
decrease. 
Figure 1 shows the result of NI, RI and CI 
while Fig. 2 gives the NTA, MTA and CTA data 
cxpresscd in arbitrary units (AU) calculated by thr 
computer from digitized data. Thr graphs show 
mean + S.E.M. 
DISCUSSION 
Recently we have shown [9] that rats with a 
nephrotic syndrome caused by puromycin develop 
changes in heart morphology similar to those of 
DOX-treated rats, a finding which questions the 
value of this species as a model to study DOX- 
induced cardiotoxicity [8]. Our present findings 
show that, in contrast to rats, mice do not develop 
a nephrotic syndrome during DOX trcatmcnt, indi- 
cating a species related variation in DOX-induced 
nephrotoxicity. These observations suggest that the 
mouse model is a bcttcr candidate for studying 
DOX-induced cardiomyopathy. Morphological 
changes following anthracyclinr treatment have 
Table 1. Histomorphometricparameters of cardiomyocytes in mice duriq and after treatment with DO.?’ compared to controls 
CI 
c II 
c III 
C IC 
C 1’ 
C \‘I1 
DOX 1 
DOX II 
DOX III 
DOX IV 
DOX V 
DOX VI 
DOX VII 
DOX VIII 
6 I 0 3.73 f 0.35 
6 2 0 3.86 -c 0.39 
6 6 0 3.81 -t 0.45 
6 8 0 3 94 2 0.43 
3 12 0 4.15 + 0.49 
4 I6 0 4.29 + 0.41 
6 I 4 3.89 * 0.58t 
6 2 8 4.78 ? 0.4”** 
6 6 I6 5.42 2 ti.57*** 
6 8 24 5.35 f 0.55*** 
6 12 2-l 5.22 2 0.40*** 
6 I4 24 5.13 ? 0.56** 
6 16 24 4.78 ? 0.63” 
6 20 24 4.84 + 0.41** 
3. I I f o:r2 
3.25 f O.i9 
3.27 f 0.43 
3.41 2 0.49 
3.62 ? O.ii 
3.87 f 0.54 
3.28 f 0.37t 
3 72 * 031* 
3.80 2 O.tl* 
4.24 f 0.43** 
4.28 2 0.30** 
4.10 r 0 39; 
4.24 + 0.48’ 
4.20 + 0.36: 
78.4 2 12.6 X40-5 f 79. I 2 61 2 0.37 
81.3 e I4 I 887.8 2 91.2 2 HH ? 0 ‘2’1 
82.3 t l4.5 885.0 % 
80.7 2 17.5 892.1 2 
81.3 2 l3.5t 883.5 ? 
95.3 2 12.2’ 995.6 2 
108.6 -t ll.l** ll70.5 f 
IN.7 2 18.2”’ 1261 0 -c 
I IG.0 * 24.6” 1002.1 t 
lll.5? 17.8** 995.5 * 
114.4 -c 16.4** 964.3 f 
Il79f l3Y** 982.6 2 
69.2 
63.2 
Uj.Gt 
75.-t* 
93.2** 
I IO I** 
87.2** 
88.4’ 
78.7” 
92 8’ 
2.94 2 0.40 
3.16 2 0.33 
2.7-l * II.46 
2.98 +- I1.ill 
3.33 * 0.4’LA 
3.60 -c 0.57’ 
3.66 * O.-tR* 
3.85 + 0 38** 
3.91 f (l.30** 
4.2!3 t 0 42** 
IO6 6 T 3 I 4 
181.5 + 13.9 
185.8 A 43.37 
172.8 + 42.q 
168.3 2 44.lt 
158.7 2 49.3* 
IliO. I -t_ 4&t* 
100.5 -C 57.6* 
154.4 ? 56.6’ 
13‘2.2 ? 48.5** 
*P < 0.0.5, *+p < 0.01, ***P < 0.001, tnot significant 
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Fig. 1. Mean values -t S.E.M. of nuclear index, reticulin index and 
capillary index during 20 weeks in mice. Solid lines show results of the 
DOX-treated mice whereas dotted lines with open circles show results of 
the control mice. 
been well documented in the heart ofvarious species 
with both light microscopic and electron micro- 
scopic examination [1,2,3,4,10-121. In contrast to 
our previous study applying morphometry in dilated 
hearts 191, all hearts in the present study were 
examined in a contracted state, achieved by their 
immersion in a CaCl, solution. This change in 
methodology was introduced because of our obser- 
vation that most of the morphometric parameters 
are sensitive to dilatation [g]. Our results have 
shown a close relationship between the cumulative 
dose of DOX and its effect on the morphometric 
parameters studied. During the observation time all 
six parameters changed with a consistent pattern. 
RI increased with the cumulative dose of DOX and 
remained stable following the last injection. The 
level of significance decreased after the end of DOX 
treatment because of the gradual increase in RI in 
the control group. The reason for this phenomenon 
is unclear, but may be related to the age of the 
animals. Reticulin is the first protein to appear 
during the course of reactive repair fibrosis [ 131. 
An increase in RI may be unfavourable for the 
functional state of the heart with respect to plas- 
ticity, elasticity and compliance. 
The remarkable increase in NTA was also corre- 
lated with the cumulative dose of DOX. After the 
last DOX injection a plateau level was observed 
which was slightly lower than the peak value. The 
increase in NTA may be related to the nuclear 
‘swelling’ which has previously been reported in 
microscopical studies [ll]. It has been suggested 
that the nuclear alterations are the results of unrav- 
elling and disaggrcgation of chromatin induced by 
the intercalating action of DOX [4]. It is known 
that DOX binds very strongly and very fast to 
DNA [14] and therefore must cross the nuclear 
membrane. The observed swelling may also be the 
result of an effect on the nuclear membrane, which 
is crossed by DOX. Nevertheless, the increase in 
NTA appears, to a certain extent, to be irreversible, 
suggesting that repair mechanisms available are not 
capable of adequately restoring the original state. 
The increase in NI during DOX treatment corre- 
lated well with an increase in the number of endo- 
thelial cells. The gradual increase in NI in the 
control group, which is likely to be an aging phenom- 
enon, resulted in a gradual drop in the level of 
significance for the difference between that in the 
DOX treated group and that in controls from 
P < 0.001 to P < 0.01. The increase in MTA was 
followed by a drop during the period after the 
completion of DOX treatment. This finding has 
NTA 
$f __---. p--p______p’____.p 
T 
2 4 8 8 10 12 14 18 18 20 
MTA 
800~ I. . . . . . - * * ( 
2 4 8 8101214181820 
CTA 
120’ . . . . . . 1 
2 4 8 8 10 12 14 18 18 20 
weeks 
Fig. 2. Mean values t S.E.M. of nuclear transsectional area, myocyte 
transsectional area and capillary transsectional area during a 20 week 
period. Values are expressed in arbitrary units (AU) calculated by the 
computerfrom digitized data. Solid lines shorn results of the DOX-treated 
mice and dotted lines shorn results ofthe control mice. 
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several possible explanations. It may be related 
to an increase in the fibre volume during DOX 
administration followed by a loss of fibres during a 
period of repair. In this respect it is of interest that 
the turnover rate of contractile proteins is in the 
order of l-2 weeks [ 151. Another reason may be a 
change in the cell membrane caused by an interac- 
tion with DOX. Finally, myocytc ‘swelling’ may be 
the result of an uptake of water through a damaged 
cell membrane, a process which may be rcverscd to 
a certain extent after exposure to DOX is discon- 
tinued. 
The increase in CI during and after DOX treat- 
ment may have been triggered by primary endo- 
thelial cell damage, considering the fact that these 
cells are even more vulnerable to DOX than myo- 
cytes [ 161. Furthermore, an increase in CI may in 
addition be a phenomenon secondary to myocardial 
dysfunction, reduced perfusion and ischaemia. In 
this context it is of interest to note that in casts of 
endothelial damage induced by irradiation the final 
stage is described as marked fibrosis [17]. Thcsc 
changes arc known to be mediated by pcroxidation 
due to the generation of free radicals. The same 
mechanisms have also been considered to be of 
importance in mediating DOX-induced cardiotox- 
icity 1181. 
Overall CTA dropped in DOX-treated mice, 
correlating with the CI because of the inverse 
relationship of these two parameters. The large 
deviation of CTA is a result of a mixed population 
of ‘old’ capillaries with a normal CTA and newly 
formed capillaries with a very small CTA. 
A great number of morphological changes in 
the heart after DOX administration have been 
described in the literature. Characteristic myocar- 
dial lesions include vacuolization, ocdema, myocy- 
tolysis, fibrosis, ultrastructural changes in nuclear, 
myofibrillar, mitochondrial and sarcotubular 
organellrs [ 121. The final stage is complete destruc- 
tion and lysis of individual cardiac myocytes 
replaced by fibrosis [4]. A grading system, which 
uses a subjective method based on cndocardial 
biopsies of the human heart, has been proposed 
by Billingham el al. [19] and has been used for 
comparative studies in animal models [ 1, lo]. The 
present study was a histomorphomctric analysis of 
hearts in mice and aimed to develop a quantitative 
model for the evaluation of anthracyclinc-induced 
cardiotoxicity. Overall, the changes in RI, NTA, 
CI and CTA observed with the present quantitivc 
model arc irreversible. The CI and CTA reached 
their highest level of significance aJier MIX trcat- 
ment, indicating that the changrs in these par- 
ameters occur slowly and are long lasting because 
repair of the injuries, if it occurs at all, takes a 
long time. NI and NTA correlate well with the 
cumulative DOX dose, while both parameters tend 
to return to normal after discontinuation of DOX 
treatment, suggesting that these changes are revcrs- 
ible. 
Comparisons of the grading system used for the 
anthracycline-induced heart toxicity 151 with the 
quantitative morphometric analysis of heart tissue 
after treatment with anthracyclincs should he pcr- 
formed in order to gain some insight into the practi- 
cal value of the latter method. Methods which 
allow a quantitation of heart tissue changes during 
anthracyclinc trcatmcnt would be better than quali- 
tative descriptions of changes in the histomorphol- 
ogy of the heart. Morphomctry, defined as the 
quantitative description of a given structure, is a 
possible way ofachievingobjectivc and rcproduciblc 
results. In contrast to subjective grading systems 
[ 191, morphomctry allows the quantitative dcscrip- 
tion of a continuous spectrum of changes in heart 
morphology. Multi-variate analyses of‘ morpho- 
metrical features arc possible and will allow the 
inter-dependencies of the different parameters stud- 
ied with this method to bc cvaluatrd. 
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